Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dentsply Sirona (XRAY) Depreciation & Amortization (CF) (2016 - 2025)

Dentsply Sirona (XRAY) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $37.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 8.82% year-over-year to $37.0 million, compared with a TTM value of $141.0 million through Dec 2025, up 6.02%, and an annual FY2025 reading of $141.0 million, up 6.02% over the prior year.
  • Depreciation & Amortization (CF) was $37.0 million for Q4 2025 at Dentsply Sirona, up from $36.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $37.0 million in Q4 2025 and bottomed at $29.0 million in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $32.4 million, with a median of $32.0 million recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) dropped 23.08% in 2021, then increased 13.79% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $30.0 million in 2021, then decreased by 3.33% to $29.0 million in 2022, then increased by 13.79% to $33.0 million in 2023, then rose by 3.03% to $34.0 million in 2024, then rose by 8.82% to $37.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for XRAY at $37.0 million in Q4 2025, $36.0 million in Q3 2025, and $34.0 million in Q2 2025.